-
公开(公告)号：EP3904501A1
公开(公告)日：2021-11-03
申请号：EP19936410.0
申请日：2019-07-02
发明人： CHEN, Jiepeng , DUAN, Lili , HONG, Lin , CHEN, Yufan , CHEN, Hongrui , JI, Yeyu , CAI, Chunli , HU, Liusong , XU, Zhikai
IPC分类号： C12N1/20 , C12P7/66 , C07C46/10 , C07C50/14 , A61K31/122 , A23L33/15 , A23L33/115 , A23L33/10 , A23L29/30 , A23L29/10 , A23L29/00 , C12R1/125
摘要： Provided is a Bacillus subtilis natto strain ST-1008, deposited under the accession number CGMCC No. 17894. Also provided is a method for producing MK-7. The method comprises: culturing the Bacillus subtilis natto strain of CGMCC No. 17894 in a culture medium so as to produce MK-7 in the strain cell and the culture medium, and recovering and purifying MK-7 from the strain cell and the culture medium. Also provided are a MK-7 preparation, a MK-7 pure premix, and a pure MK-7.
-
公开(公告)号：EP3838911A1
公开(公告)日：2021-06-23
申请号：EP19925351.9
申请日：2019-04-16
发明人： CHEN, Jiepeng , DUAN, Lili , CHEN, Hongrui , HU, Liusong , CHEN, Yufan , HONG, Lin , XU, Zhikai , YE, Honglin , JI, Yeyu , CAI, Chunli
摘要： anticoagulant activity of the hirudin mutant HV2-Lys47 is greater than or equal to 18000ATU/mg.
24. The anticoagulant blood collection tube according to claim 22 or 23, wherein the hirudin mutant HV2-Lys47 is a hirudin mutant HV2-Lys47 produced according to the method of any one of claims 1-11, or the hirudin mutant HV2-Lys47 is the hirudin mutant HV2-Lys47 according to claim 13.-
公开(公告)号：EP3892715A1
公开(公告)日：2021-10-13
申请号：EP19936116.3
申请日：2019-07-02
发明人： CHEN, Jiepeng , DUAN, Lili , HONG, Lin , JI, Yeyu , CHEN, Hongrui , CAI, Chunli , HU, Liusong , XU, Zhikai , CHEN, Yufan
摘要： Disclosed are a strain for producing nattokinase and a production method therefor. In particular, the present invention involves a novel strain capable of producing nattokinase, i.e. Bacillus subtilis natto ST-1086, deposited at the China General Microbiological Culture Collection Center under CGMCC No. 17895. The present invention further involves a method for producing a nattokinase product by means of using the novel strain CGMCC No. 17895 of the present application, wherein the resulting nattokinase product can be used as a drug for dissolving thrombi. The present invention further involves the use of the nattokinase product of the present application for preparing a composition for dissolving thrombi and in a method for treating thrombi.
-
-
搜索结果
3 条记录 (耗时 0.009 秒)
